2020
DOI: 10.20944/preprints202008.0490.v2
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma

Abstract: β2-m, β2-microglobulin; CAF, cancer associated fibroblast; CSC, cancer stem cell; CTL, cytotoxic T lymphocyte; DC, dendritic cell; ECM, extracellular matrix; EGF-R, epidermal growth factor receptor; ER, endoplasmic reticulum; FDA, Food and Drug Administration; HLA, human leukocyte antigen; HNSCC, head and neck squamous cell carcinoma; HPV, human papilloma virus; ICP immune checkpoint; ICPi, immune checkpoint inhibitor; IFN, interferon; LMP, low molecular weight protein; mAb, monoclonal antibo… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(1 citation statement)
references
References 75 publications
0
1
0
Order By: Relevance
“…These drugs are designed to enhance antitumor immune activity by blocking the PD-1/PD-L1 pathway. Currently, numerous clinical trials are testing the potential synergistic combination of anti-PD-1/PD-L1 with radiotherapy and platinum or cetuximab, or anti-PD-1/PD-L1 used in a neoadjuvant setting [116][117][118].…”
Section: Targeting Immunomodulation That Clears Damaged Cells and Adapts To Chronic Stressmentioning
confidence: 99%
“…These drugs are designed to enhance antitumor immune activity by blocking the PD-1/PD-L1 pathway. Currently, numerous clinical trials are testing the potential synergistic combination of anti-PD-1/PD-L1 with radiotherapy and platinum or cetuximab, or anti-PD-1/PD-L1 used in a neoadjuvant setting [116][117][118].…”
Section: Targeting Immunomodulation That Clears Damaged Cells and Adapts To Chronic Stressmentioning
confidence: 99%